Trials / Terminated
TerminatedNCT01048593
Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Cataract Surgery Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- ICON Bioscience Inc · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.
Detailed description
All patients received active treatment in this study. Dose group 1 received 114ug of dexamethasone, Dose group 2 received 513ug and Dose group 3 received 684ug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI-10090 | Single intraocular injection |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-05-01
- Completion
- 2010-06-01
- First posted
- 2010-01-13
- Last updated
- 2018-12-04
- Results posted
- 2012-08-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01048593. Inclusion in this directory is not an endorsement.